Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28218206 | 0.88 | CYP19A1 (0.37) | L3MBTL1CYP19A1BRD4HCAR2RXFP1 | |
| SCHEMBL16519369 | 0.80 | PTGER1 (0.42) | L3MBTL1CYP19A1BRD4HCAR2RXFP1 | |
| SCHEMBL28896966 | 0.79 | CYP19A1 (0.32) | CYP19A1BRD4 | |
| SCHEMBL28314805 | 0.79 | L3MBTL1 (0.40) | L3MBTL1BRD4HCAR2TYRRXFP1 | |
| SCHEMBL4934202 | 0.78 | HCAR2 (0.43) | L3MBTL1HCAR2CYP2C19PLA2G4A | |
| SCHEMBL29094923 | 0.75 | HCAR2 (0.37) | L3MBTL1CYP19A1HCAR2RXFP1PTGS1 | |
| SCHEMBL21564316 | 0.74 | HCAR2 (0.41) | L3MBTL1BRD4HCAR2RXFP1PTGS1 | |
| SCHEMBL15903278 | 0.72 | HCAR2 (0.35) | CYP19A1HCAR2RXFP1PTGS1PTGS2 | |
| SCHEMBL6494245 | 0.72 | RXFP1 (0.36) | L3MBTL1BRD4HCAR2RXFP1PTGS1 | |
| SCHEMBL1268994 | 0.70 | WDR5 (0.36) | CYP19A1HCAR2RXFP1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4692069-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4110317-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | KCNT1, SCN1A, KCNT2 | L3MBTL1 296/4885CYP19A1 3935/4885BRD4 2646/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | L3MBTL1 656/4885CYP19A1 3818/4885BRD4 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.